Central Texas Neurology Consultants

Recent papers from Central Texas Neurology Consultants

1. Buntanetap treatment in mild to moderate Alzheimer’s disease: phase 2/3 studynpj Dementia · 2026
2. Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain StimulationAdvances in Therapy · 2026
3. The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s diseaseNature Aging · 2026
4. Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS TrialNeurology and Therapy · 2022
5. Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisNew England Journal of Medicine · 2022
6. A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's DiseaseClinical Pharmacology in Drug Development · 2022
7. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyMultiple Sclerosis Journal · 2021
8. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple SclerosisCNS Drugs · 2021
9. B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year reportJournal of Neuroimmunology · 2021
10. CLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tablets in Suboptimally Controlled Relapsing Multiple SclerosisNeurodegenerative Disease Management · 2021
11. Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims databaseJournal of Medical Economics · 2020
12. Timing of the Sense of Volition in Patients With SchizophreniaFrontiers in Neuroscience · 2020
13. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple SclerosisJAMA Neurology · 2020
14. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential TremorTremor and Other Hyperkinetic Movements · 2020
15. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisNeurology · 2020
16. Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarateMultiple Sclerosis and Related Disorders · 2020
17. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosisMultiple Sclerosis Journal · 2020
18. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disabilityMultiple Sclerosis Journal - Experimental Translational and Clinical · 2020
19. Lymphocyte counts and infection ratesNeurology Neuroimmunology & Neuroinflammation · 2019
20. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patientsJournal of Neuroimmunology · 2019